MOGAT3 and neoplasm: Monotherapy with Pf reduced the intratumoral DAG, but did not affect resistant PDX tumor growth, suggesting that MOGAT3-regulated levels of intratumoral DAG determine the treatment response to dual therapy (Figure 3, I–K).